title: Biological aspects of neuroblastomas identified by mass screening in Quebec.
abstract: BACKGROUND
  Neuroblastoma has several characteristics that suggest that preclinical diagnosis might improve outcome. Therefore, the Quebec Neuroblastoma Screening Project was undertaken from 1989 to 1994 to examine infants at 3 weeks and 6 months by measuring urinary catecholamine metabolites.
  
  
  METHODS
  Over the 5-yr period, 45 tumors were detected by screening, 20 were identified clinically prior to the third week, and 64 were identified clinically at a later time. We analyzed available tumors for Shimada histopathology, tumor ploidy, MYCN copy number and serum ferritin.
  
  
  RESULTS
  Of the tumors detected by screening, only 2 of 45 tested had unfavorable histology, 2 of 45 had diploid or tetraploid DNA content, 0 of 43 had MYCN amplification, and 4 of 44 had elevated serum ferritin. All of these patients are alive and well. The 20 patients detected prior to the 3-week screen had similar biological characteristics. In contrast, of the patients detected clinically after 3 weeks of age, 19 of 51 testedhad unfavorable histology, 25 of 66 had diploid or tetraploid tumors, 12 of 56 had MYCN amplification, and 14 of 54 had elevated ferritin.
  
  
  CONCLUSIONS
  The difference between the screened and clinically detected cases was highly significant for each biological variable. Preliminary data on other biological variables, such as neurotrophin expression and allelic loss on 1 p in these patients are consistent with the above findings. These data suggest that mass screening for neuroblastoma at or before 6 months of age detects almost exclusively tumors that have favorable biological characteristics, many of which might have regressed spontaneously. Thus, continued mass screening for neuroblastoma at 6 months is unlikely to accomplish its intended goal, and should probably be discontinued.
authors.affiliation: Division of Oncology, Children's Hospital of Philadelphia, PA 19104-4318, USA. brodeur@email.chop.edu
authors.forename: G M
authors.initials: GM
authors.lastname: Brodeur
authors.forename: A T
authors.initials: AT
authors.lastname: Look
authors.forename: H
authors.initials: H
authors.lastname: Shimada
authors.forename: V M
authors.initials: VM
authors.lastname: Hamilton
authors.forename: J M
authors.initials: JM
authors.lastname: Maris
authors.forename: H W
authors.initials: HW
authors.lastname: Hann
authors.forename: J M
authors.initials: JM
authors.lastname: Leclerc
authors.forename: M
authors.initials: M
authors.lastname: Bernstein
authors.forename: L C
authors.initials: LC
authors.lastname: Brisson
authors.forename: J
authors.initials: J
authors.lastname: Brossard
authors.forename: B
authors.initials: B
authors.lastname: Lemieux
authors.forename: M
authors.initials: M
authors.lastname: Tuchman
authors.forename: W G
authors.initials: WG
authors.lastname: Woods
mesh_terms: D000367:Age Factors; D014408:Biomarkers, Tumor; D002395:Catecholamines / Q000652:urine; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics / Q000648:ultrastructure; D015331:Cohort Studies; D005293:Ferritins / Q000032:analysis / Q000097:blood; D005784:Gene Amplification; D016259:Genes, myc; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008403:Mass Screening; D015997:Neonatal Screening; D009447:Neuroblastoma / Q000453:epidemiology* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D010808:Physical Examination; D011003:Ploidies; D011379:Prognosis; D011792:Quebec / Q000453:epidemiology
chemical_list: D014408:Biomarkers, Tumor; D002395:Catecholamines; D005293:Ferritins